# A Novel Extracorporeal Liver Support Therapy In ALCF and to Evaluate the Efficacy of DIALIVE 2.0, a Liver Dialysis Device.

> **NCT07347275** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Yaqrit Ltd** · enrollment: 72 (estimated)

## Conditions studied

- Acute-on-Chronic Liver Failure (ACLF)
- Liver Cirrhosis

## Interventions

- **OTHER:** Standard of Care (Investigator Choice)
- **DEVICE:** DIALIVE 2.0 liver dialysis Device plus available Standard of Care

## Key facts

- **NCT ID:** NCT07347275
- **Lead sponsor:** Yaqrit Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2027-03
- **Final completion:** 2027-05
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07347275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07347275, "A Novel Extracorporeal Liver Support Therapy In ALCF and to Evaluate the Efficacy of DIALIVE 2.0, a Liver Dialysis Device.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07347275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*